Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04142359 · ClinicalTrials.gov registry record
PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)
A clinical trial, sponsored by Altor BioScience.
- Terminated
- Registry status
- 1
- Enrollment target
NCT04142359: Clinical Trial study, sponsored by Altor BioScience.
NCT04142359 is a clinical trial that was terminated before completion, run by Altor BioScience. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04142359 was terminated before completion, sponsored by Altor BioScience.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
Non-interventional PK sub-study of QUILT-3.032 (CA-ALT-803-01-16) and QUILT-2.005 (CA-ALT-803-01-14)
Primary Outcome
Half-life (t½)
Interventions
- BIOLOGICAL BCG in Combination with N-803
- DRUG N-803 alone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2020-04-06 |
Why NCT04142359 stopped before completion
NCT04142359 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which BCG in Combination with N-803 is the first listed.
NCT04142359 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04142359 about?
NCT04142359 is a clinical study titled "PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)". Non-interventional PK sub-study of QUILT-3.032 (CA-ALT-803-01-16) and QUILT-2.005 (CA-ALT-803-01-14)
What is the current status of trial NCT04142359?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2019-12-09. Estimated completion is 2020-04-06.
What interventions are being tested in trial NCT04142359?
The interventions under investigation include: BCG in Combination with N-803 (BIOLOGICAL), N-803 alone (DRUG).
Who is sponsoring clinical trial NCT04142359?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI